Trexquant Investment LP Has $4.16 Million Position in Elanco Animal Health Incorporated (NYSE:ELAN)

Trexquant Investment LP lifted its position in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 85.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 343,883 shares of the company’s stock after purchasing an additional 158,520 shares during the quarter. Trexquant Investment LP’s holdings in Elanco Animal Health were worth $4,164,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. Geode Capital Management LLC lifted its holdings in Elanco Animal Health by 4.0% during the fourth quarter. Geode Capital Management LLC now owns 8,180,840 shares of the company’s stock worth $99,102,000 after acquiring an additional 312,165 shares in the last quarter. Orion Portfolio Solutions LLC raised its position in shares of Elanco Animal Health by 14.3% during the fourth quarter. Orion Portfolio Solutions LLC now owns 33,396 shares of the company’s stock worth $404,000 after purchasing an additional 4,169 shares during the period. Norges Bank bought a new position in shares of Elanco Animal Health during the 4th quarter valued at about $47,424,000. Blair William & Co. IL grew its position in shares of Elanco Animal Health by 17.3% in the 4th quarter. Blair William & Co. IL now owns 70,430 shares of the company’s stock valued at $853,000 after purchasing an additional 10,400 shares during the period. Finally, WINTON GROUP Ltd acquired a new stake in Elanco Animal Health during the 4th quarter worth approximately $141,000. 97.48% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Elanco Animal Health news, Director Lawrence Erik Kurzius purchased 10,000 shares of Elanco Animal Health stock in a transaction that occurred on Tuesday, March 11th. The stock was acquired at an average price of $10.20 per share, for a total transaction of $102,000.00. Following the completion of the acquisition, the director now owns 111,459 shares of the company’s stock, valued at approximately $1,136,881.80. This trade represents a 9.86 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. 0.57% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. Stifel Nicolaus reduced their price target on shares of Elanco Animal Health from $18.00 to $16.00 and set a “buy” rating for the company in a report on Friday, February 21st. Barclays lowered their target price on Elanco Animal Health from $20.00 to $19.00 and set an “overweight” rating for the company in a report on Wednesday, February 26th. Piper Sandler cut their price target on Elanco Animal Health from $16.00 to $12.00 and set a “neutral” rating on the stock in a report on Thursday, March 6th. Morgan Stanley decreased their price objective on Elanco Animal Health from $14.00 to $13.00 and set an “equal weight” rating for the company in a report on Wednesday, February 26th. Finally, UBS Group dropped their target price on Elanco Animal Health from $18.00 to $17.00 and set a “buy” rating on the stock in a research report on Wednesday, February 26th. Four investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $15.17.

Elanco Animal Health Price Performance

Shares of NYSE ELAN opened at $9.17 on Friday. Elanco Animal Health Incorporated has a fifty-two week low of $8.80 and a fifty-two week high of $18.80. The stock has a market capitalization of $4.55 billion, a price-to-earnings ratio of 22.91, a PEG ratio of 2.50 and a beta of 1.44. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31. The business has a 50-day moving average of $11.04 and a 200-day moving average of $12.28.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings results on Tuesday, February 25th. The company reported $0.14 earnings per share for the quarter, missing the consensus estimate of $0.15 by ($0.01). Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The company had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.01 billion. During the same period last year, the firm earned $0.08 EPS. The firm’s revenue for the quarter was down 1.4% compared to the same quarter last year. As a group, sell-side analysts predict that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.